First day for trading in TO1 series warrants

As previously communicated, 2cureX AB (“2cureX” or the “Company”) has carried out a directed issue of shares and warrants of series TO1 (“Warrants”) and distributed Warrants to the shareholders in the Company. The first day of trading with the Warrants on Nasdaq First North Growth Market is August 6, 2020.

Terms of warrants of series TO1

Each warrant of series TO1 will give the holder the right to subscribe for one (1) new share in 2cureX at a subscription price corresponding to 70 per cent of the average volume-weighted share price of the company´s share according to Nasdaq First North Growth Market’s official price statistics during the period from April 9, 2021 to April 22, 2021. However, the subscription price shall not exceed SEK 28.88 per new share, and not be less than the quota value of the Company’s share. The exercise period to subscribe for new shares with warrants from series TO1 will be from April 26, 2021 to May 7, 2021.

Given fully exercise of the warrants of series TO1, 2cureX can be provided with up to approximately SEK 70.9 million, depending on the subscription price.

Advisor

Mangold Fondkommission AB was financial advisor and Eversheds Sutherland Advokatbyrå AB was legal advisor in connection with the directed issue and the distribution of Warrants to the shareholders.

For more information about 2cureX, please contact:

Ole Thastrup, CEO

E-post: ot@2curex.com

Telefon: +45 22 11 53 99

www.2curex.com

Certified Adviser

Redeye AB

Telefon: +46 8 121 576 90

E-mail: certifiedadviser@redeye.se

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany, Sweden and United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program.

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX").

About Us

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients. IndiTreat® is currently being clinically validated in colorectal and ovarian cancer. The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

Subscribe

Documents & Links